FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220792405> ?p ?o ?g. }

• W4220792405 abstract "EZH2 inhibitors (EZH2i), a class of small-molecule inhibitors that target EZH2 to exert anti-tumor functions, have just been approved by the US Food and Drug Administration (FDA) in treatment of adults and adolescents with locally advanced or metastatic epithelioid sarcoma. The application of EZH2i in several solid tumors is still in different stages of clinical trials and needs to be further validated. As a key epigenetic regulator, besides its role in controlling the proliferation of tumor cells, EZH2 has been implicated in the regulation of various immune cells including macrophages. But there are still controversial research results at present. Colorectal cancer (CRC) is a common malignant tumor that highly expresses EZH2, which has the third highest incidence and is the second leading cause of cancer-related death worldwide. Studies have shown that the numbers of M2-type tumor-associated macrophages (TAMs) are highly associated with the progression and metastasis of CRC. In the current study, we aim to investigate how EZH2 modulates the polarization of macrophages in the tumor microenvironment (TME) of CRC, and compare the role of two different EZH2 inhibitors, EPZ6438 and GSK126. We applied a 3D culture method to demonstrate that EZH2i did indeed suppress the proliferation of CRC cells in vitro. In vivo, we found that the percentage of CD206+ macrophages of the TME was decreased under the treatment of EPZ6438, but it increased upon GSK126 treatment. Besides, in the co-culture system of macrophages and CRC cells, EPZ6438 led to significant elevation of M1 markers and reduction of M2 markers. Furthermore, mechanistic studies validated by ChIP-qPCR demonstrated that EZH2i inhibit EZH2-mediated H3K27me3 levels on the promoters of STAT3, an essential transcription factor for M1 macrophage polarization. Therefore, our data suggested that EZH2i not only suppress CRC cell proliferation directly, but also regulate macrophage by skewing M2 into effector M1 macrophage to exert a tumor suppressive effect. Moreover, our study provided new insight for better understanding of the role of two kinds of EZH2i: EPZ6438 and GSK126, which may pave the way in treating CRC by targeting cancer cells and immune cells via this epigenetic approach in the future." @default.
• W4220792405 created "2022-04-03" @default.
• W4220792405 creator A5001906955 @default.
• W4220792405 creator A5003642180 @default.
• W4220792405 creator A5004998822 @default.
• W4220792405 creator A5011703930 @default.
• W4220792405 creator A5019257182 @default.
• W4220792405 creator A5025086167 @default.
• W4220792405 creator A5032447166 @default.
• W4220792405 creator A5037989560 @default.
• W4220792405 creator A5044897313 @default.
• W4220792405 creator A5045769684 @default.
• W4220792405 creator A5046794267 @default.
• W4220792405 creator A5053034261 @default.
• W4220792405 creator A5068242622 @default.
• W4220792405 creator A5091892657 @default.
• W4220792405 date "2022-04-01" @default.
• W4220792405 modified "2023-10-17" @default.
• W4220792405 title "EZH2 Inhibitors Suppress Colorectal Cancer by Regulating Macrophage Polarization in the Tumor Microenvironment" @default.
• W4220792405 cites W1971752166 @default.
• W4220792405 cites W1975476791 @default.
• W4220792405 cites W2004380688 @default.
• W4220792405 cites W2005293755 @default.
• W4220792405 cites W2015132841 @default.
• W4220792405 cites W2030342863 @default.
• W4220792405 cites W2078490888 @default.
• W4220792405 cites W2107816687 @default.
• W4220792405 cites W2131464730 @default.
• W4220792405 cites W2199397492 @default.
• W4220792405 cites W2320983896 @default.
• W4220792405 cites W2529083585 @default.
• W4220792405 cites W2579984573 @default.
• W4220792405 cites W2761941966 @default.
• W4220792405 cites W2769376917 @default.
• W4220792405 cites W2792926177 @default.
• W4220792405 cites W2795964681 @default.
• W4220792405 cites W2803619785 @default.
• W4220792405 cites W2884747526 @default.
• W4220792405 cites W2886753951 @default.
• W4220792405 cites W2911341716 @default.
• W4220792405 cites W2931042200 @default.
• W4220792405 cites W2948655969 @default.
• W4220792405 cites W2955675764 @default.
• W4220792405 cites W2970734757 @default.
• W4220792405 cites W2971714046 @default.
• W4220792405 cites W2973106464 @default.
• W4220792405 cites W2977149272 @default.
• W4220792405 cites W2977474827 @default.
• W4220792405 cites W2991348174 @default.
• W4220792405 cites W3011290602 @default.
• W4220792405 cites W3013522609 @default.
• W4220792405 cites W3022070645 @default.
• W4220792405 cites W3045753156 @default.
• W4220792405 cites W3089101554 @default.
• W4220792405 cites W3092226358 @default.
• W4220792405 cites W3111113986 @default.
• W4220792405 cites W3115739536 @default.
• W4220792405 cites W3139001557 @default.
• W4220792405 cites W3154042197 @default.
• W4220792405 cites W3198353783 @default.
• W4220792405 cites W4205285591 @default.
• W4220792405 cites W4211090034 @default.
• W4220792405 cites W4241962913 @default.
• W4220792405 doi "https://doi.org/10.3389/fimmu.2022.857808" @default.
• W4220792405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35432300" @default.
• W4220792405 hasPublicationYear "2022" @default.
• W4220792405 type Work @default.
• W4220792405 citedByCount "9" @default.
• W4220792405 countsByYear W42207924052022 @default.
• W4220792405 countsByYear W42207924052023 @default.
• W4220792405 crossrefType "journal-article" @default.
• W4220792405 hasAuthorship W4220792405A5001906955 @default.
• W4220792405 hasAuthorship W4220792405A5003642180 @default.
• W4220792405 hasAuthorship W4220792405A5004998822 @default.
• W4220792405 hasAuthorship W4220792405A5011703930 @default.
• W4220792405 hasAuthorship W4220792405A5019257182 @default.
• W4220792405 hasAuthorship W4220792405A5025086167 @default.
• W4220792405 hasAuthorship W4220792405A5032447166 @default.
• W4220792405 hasAuthorship W4220792405A5037989560 @default.
• W4220792405 hasAuthorship W4220792405A5044897313 @default.
• W4220792405 hasAuthorship W4220792405A5045769684 @default.
• W4220792405 hasAuthorship W4220792405A5046794267 @default.
• W4220792405 hasAuthorship W4220792405A5053034261 @default.
• W4220792405 hasAuthorship W4220792405A5068242622 @default.
• W4220792405 hasAuthorship W4220792405A5091892657 @default.
• W4220792405 hasBestOaLocation W42207924051 @default.
• W4220792405 hasConcept C104317684 @default.
• W4220792405 hasConcept C121608353 @default.
• W4220792405 hasConcept C126322002 @default.
• W4220792405 hasConcept C202751555 @default.
• W4220792405 hasConcept C203014093 @default.
• W4220792405 hasConcept C2776107976 @default.
• W4220792405 hasConcept C2776682551 @default.
• W4220792405 hasConcept C2779013556 @default.
• W4220792405 hasConcept C2779244956 @default.
• W4220792405 hasConcept C2779482015 @default.
• W4220792405 hasConcept C41091548 @default.
• W4220792405 hasConcept C50171091 @default.
• W4220792405 hasConcept C502942594 @default.
• W4220792405 hasConcept C526805850 @default.

• next